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Abstract
Stenotrophomonas maltophilia (SM) is an important nosocomial pathogen that exhibits intrinsic resistance to various
antimicrobial agents. However, the risk factors for SM bacteraemia have not been sufficiently evaluated. From January 2005
to September 2012, we retrospectively compared the clinical backgrounds and outcomes of SM bacteraemic patients (SM
group) with those of bacteraemic patients due to Pseudomonas aeruginosa (PA group) or Acinetobacter species (AC group).
DNA genotyping of the SM isolates using the Diversilab system was performed to investigate the genetic relationships
among the isolates. The SM, PA, and AC groups included 54, 167, and 69 patients, respectively. Nine of 17 patients in the SM
group receiving trimethoprim-sulfamethoxazole prophylaxis developed SM bacteraemia. Independent risk factors for SM
bacteraemia were the use of carbapenems and antipseudomonal cephalosporins and SM isolation within 30 days prior to
the onset of bacteraemia. Earlier SM isolation was observed in 32 of 48 patients (66.7%) with SM bacteraemia who
underwent clinical microbiological examinations. Of these 32 patients, 15 patients (46.9%) had the same focus of
bacteraemia as was found in the previous isolation site. The 30-day all-cause mortality rate among the SM group (33.3%)
was higher than that of the PA group (21.5%, p = 0.080) and the AC group (17.3%, p = 0.041). The independent factor that
was associated with 30-day mortality was the SOFA score. DNA genotyping of SM isolates and epidemiological data
suggested that no outbreak had occurred. SM bacteraemia was associated with high mortality and should be considered in
patients with recent use of broad-spectrum antibiotics or in patients with recent isolation of the organism.
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Introduction
Stenotrophomonas maltophilia (SM) is an emerging nosocomial
pathogen. In a surveillance performed from 1997 to 1999 in the
Asia-Pacific, Europe, Latin America, Canada, and the United
States regions, SM was the third most frequently isolated non-
fermentative gram-negative bacilli, following Pseudomonas aeru-
ginosa (PA) and Acinetobacter species (AC) [1]. SM is intrinsically
resistant to beta-lactams or aminoglycosides via the chromosomal
resistance genes L1 and L2 beta-lactamase and aminoglycoside-
modifying enzymes [2]. Trimethoprim-sulfamethoxazole (TMP-
SMZ) is the first-line therapeutic drug for the treatment of SM,
and it is recommended that severe infections be treated with a high
dose of TMP-SMZ, similar to the dose used to treat Pneumocystis
jirovecii [2]. Thus, the therapeutic options for SM are quite
different from those available for other non-fermentative gram-
negative bacilli, and the appropriate antimicrobial therapy is often
delayed [3]. Therefore, a high crude mortality rate among SM
bacteraemic patients has been reported, ranging from 14% to 69%
[4]. Several studies have evaluated the risk factors for SM
bacteraemia, but these studies have involved small populations or
patients with specific medical conditions, such as haematological
malignancies [5–9]. No study has compared SM bacteraemia in all
hospitalised patients with bacteraemias due to PA or AC, which
are the most important nosocomial pathogens. To elucidate the
clinical characteristics of SM bacteraemia, we compared the
antimicrobial susceptibility, clinical backgrounds, and prognostic
factors of SM bacteraemic patients with those of patients suffering
from bacteraemia due to Pseudomonas aeruginosa (PA) or
Acinetobacter species (AC). The risk factors for 30-day mortality
were evaluated in the SM bacteraemic patients. For the SM
isolates, DNA genotyping was also conducted to investigate the
genetic relationships among the SM isolates.
Methods
Ethics statement
The Ethics Committee of Kyoto University Graduate School of
Medicine (E-2070) approved this study and waived the need for
obtaining informed consent from each patient.
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Table 1. Clinical characteristics of S. maltophilia bacteraemic patients compared to P. aeruginosa and Acinetobacter species
bacteraemic patients: univariate analysis.
Clinical backgrounds SM (N=54) PA (N=167) AC (N=69) SM vs. PA SM vs. AC
no. (%) no. (%) no. (%) p-value p-value
Age, median (IQR) 56 (39.8–65.3) 61 (49–70) 62 (37.5–72) 0.033 0.133
Sex 26 (48.1) 99 (59.3) 39 (56.5) 0.151 0.356
Underlying comorbidities
Solid malignancy 21 (38.9) 52 (31.1) 23 (33.3) 0.292 0.524
Haematological malignancy 7 (13.0) 35 (21.0) 8 (11.6) 0.193 0.818
Diabetes 12 (22.2) 39 (23.4) 12 (17.4) 0.864 0.502
Renal dysfunction 9 (16.7) 33 (19.8) 13 (18.8) 0.614 0.755
Heart diseases 8 (14.8) 16 (9.6) 8 (11.6) 0.283 0.598
Liver diseases 19 (35.2) 47 (28.1) 14 (20.3) 0.326 0.064
Respiratory diseases 3 (5.6) 14 (8.4) 6 (8.7) 0.769 0.730
Autoimmune diseases 9 (16.7) 22 (13.2) 10 (14.5) 0.521 0.741
Charlson score, median (IQR) 3 (2–5) 3 (2–5) 3 (2–4) 0.858 0.218
Medical condition
Nosocomial bacteraemiaa 54 (100.0) 137 (82.0) 62 (89.9) ,0.001 0.018
Duration of hospital stay, median (IQR) 50 (28–95) 27 (13–52) 29 (13–56) ,0.001 0.002
SOFA score, median (IQR) 6 (2–10) 4 (2–8) 3 (1–6) 0.070 0.002
Solid organ transplantation 17 (31.5)b 45 (26.9) 10 (14.5) 0.519 0.024
Bone marrow transplantation 5 (9.3) 11 (6.6) 2 (2.9) 0.548 0.238
Operation within previous 30 days 17 (31.5) 37 (22.2) 14 (20.3) 0.166 0.156
Mechanical ventilation 22 (40.7) 25 (15.0) 7 (10.1) ,0.001 ,0.001
CRRT 10 (18.5) 8 (4.7) 1 (1.4) ,0.001 0.001
Maintenance-haemodialysis 3 (5.6) 8 (4.8) 4 (5.8) 0.732 1.000
Neutropenia 8 (14.8) 41 (24.6) 4 (5.8) 0.134 0.128
Central venous catheter 36 (66.7) 81 (48.5) 29 (42.0) 0.020 0.005
Urethral catheter 34 (63.0) 64 (38.3) 25 (36.2) 0.002 0.003
Nasogastric tube 29 (53.7) 43 (25.7) 22 (31.9) ,0.001 0.015
Drainage tube 31 (57.4) 52 (31.1) 26 (37.7) 0.001 0.029
Immunosuppressive agents 29 (53.7) 95 (56.9) 29 (42.0) 0.682 0.076
ICU admission 19 (35.2) 16 (9.6) 7 (10.1) ,0.001 0.001
Previous antimicrobial therapy
Carbapenems 22 (40.7) 24 (24.0) 10 (14.5) ,0.001 0.001
Glycopeptides 29 (53.7)c 32 (19.2) 18 (26.1) ,0.001 0.002
Antipseudomonal cephalosporins 30 (55.6) 34 (20.4) 12 (17.4) ,0.001 ,0.001
Non-antipseudomonal cephalosporins 8 (14.8) 23 (13.8) 10 (14.5) 0.848 0.960
Antipseudomonal penicillins 6 (11.1) 15 (9.0) 5 (7.2) 0.643 0.533
Non-antipseudomonal penicillins 4 (7.4) 17 (10.2) 5 (7.2) 0.790 1.000
Fluoroquinolones 9 (16.7) 16 (9.6) 7 (10.1) 0.153 0.289
Aminoglycosides 5 (9.3) 8 (4.8) 0 (0.0) 0.314 0.015
TMP-SMZ 17 d (31.5) 61 (36.5) 19 (27.5) 0.500 0.633
Minocycline 4 (7.4) 1 (0.6) 1 (1.4) 0.013 0.168
SM isolation within 30 days 32 (66.7e) 10 (8.3e) 4 (8.3e) ,0.001 ,0.001
Site of infection
Respiratory 8 (14.8) 20 (11.9) 2 (2.9) 0.586 0.019
Catheter-related 12 (22.2) 21 (12.5) 15 (21.7) 0.080 0.949
Intra-abdominal 12 (22.2) 25 (15.0) 7 (10.1) 0.215 0.066
Urinary tract 0 (0.0) 24 (14.4) 4 (5.8) 0.002 0.130
Skin and soft tissue 0 (0.0) 9 (5.4) 2 (2.9) 0.117 0.503
Primary 22 (40.7) 68 (40.7) 38 (55.1) 0.998 0.082
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Setting and study design
This study was conducted at Kyoto University Hospital, an
1121-bed tertiary-care hospital in Kyoto, Japan. All of the
bacteraemic episodes in the hospital were reported to and were
followed up by our infectious disease physicians. From January
2005 to September 2012, all patients who had positive blood
cultures for SM, PA, or AC were enrolled. Patients who had blood
cultures that were positive for more than one bacterial species of
SM, PA, and AC were excluded. Each patient was included in the
study only once, at the time of the initial blood culture. A case
control-control study design was used. The cases consisted of
patients with SM bacteraemia (SM group), and the first and
second control groups was consisted of patients with PA
bacteraemia (PA group), or patients with AC bacteraemia (AC
group), respectively.
Variables and definitions
The clinical information acquired from the medical charts
included age, sex, duration of hospital stay, presence of
polymicrobial infection, underlying comorbidities, Charlson score
[10], Sequential Organ Failure Assessment (SOFA) score [11],
presence of septic shock [12], history of organ transplantation,
surgery within 30 days, neutropenia, administration of immuno-
suppressive drugs, use of mechanical support or indwelling
catheters, ICU stay and duration, isolation of SM within 30 days,
clinical specimen types from which SM was isolated, focus of
infection, empirical antimicrobial therapy, and 30-day mortality
rate. Polymicrobial infection was defined as the identification of
two or more bacterial species in blood culture samples collected
within 72 hours. Nosocomial bacteraemia was defined as
bacteraemia that occurred 72 hours or more after admission.
Neutropenia was defined as an absolute neutrophil count less than
500/ml at the onset of bacteraemia. The administration of
immunosuppressive drugs included corticosteroids or other
immunosuppressive drugs within 14 days before the onset of
bacteraemia. Previous antimicrobial therapy was defined as the
administration of antibiotics for more than 48 hours within 14
days prior to the onset of bacteraemia. The isolation of SM within
30 days was defined as the isolation of SM from an extra-blood site
between 1 and 30 days prior to the onset of bacteraemia. The
focus of infection was clinically determined based on an active
infection site and on the isolation of the organism from the site
coincident with the onset of bacteraemia. Empiric antimicrobial
therapy was considered to be inappropriate if an active
antimicrobial agent, as determined by in vitro susceptibility
testing, was not administered during the first 72 hours after the
blood sample was obtained. The attributable mortality (bacterae-
mia-related deaths) was judged by our two infectious diseases
physicians when the patient would not have died in the absence of
bacteraemia.
To evaluate the risk factors for the 30-day all-cause mortality
rate of the SM group, the clinical background, severity of illness,
and rate of appropriate therapy among the patients who did not
survive were compared with those of the patients who survived.
Antimicrobial susceptibilities
Blood culture samples were processed using the BACTEC 9240
system (Becton Dickinson Microbiology Systems, Sparks, MD,
Table 1. Cont.
Clinical backgrounds SM (N=54) PA (N=167) AC (N=69) SM vs. PA SM vs. AC
no. (%) no. (%) no. (%) p-value p-value
Inappropriate empiric therapy 17 (31.5) 9 (5.4) 4 (5.8) ,0.001 ,0.001
30-day mortality
All-cause mortality 18 (33.3) 36 (21.6) 12 (17.4) 0.080 0.041
Attributable mortality 12 (22.2) 27 (16.2) 7 (10.1) 0.310 0.066
SM, S. maltophilia; PA, P. aeruginosa; AC, Acinetobacter species; IQR, interquartile range; SOFA, Sequential Organ Failure Assessment; CRRT, continuous renal replacement
therapy; ICU, Intensive care unit; TMP-SMZ, trimethoprim-sulfamethoxazole.
aAll of the patients other than those with nosocomial bacteraemia had underlying comorbidities and had been followed up in the outpatient department.
bAntipseudomonal cephalosporins or carbapenems were administered in 13 patients (76.4%).
cAntipseudomonal cephalosporins or carbapenems were administered in 26 patients (89.6%).
dAll of these patients received TMP-SMZ for prophylaxis against Pneumocystis jirovecii pneumonia.
eMicrobiological examinations were performed in 48 patients (88.9%) in the SM group, in 120 patients (71.9%) in the PA group, and in 48 patients (69.6%) in the AC
group. The percentages in the Table represent the number of patients with SM isolation divided by the number of patients who underwent microbiological
examination.
doi:10.1371/journal.pone.0112208.t001
Table 2. Risk factors of S. maltophilia bacteraemia compared to the bacteremias due to P. aeruginosa and Acinetobacter species:
multivariate analysis.
Clinical backgrounds SM vs. PA SM vs. AC
OR (95%CI) p-value OR (95%CI) p-value
Use of carbapenems 2.8 (1.1–6.8) ,0.001 3.0 (1.0–9.0) 0.047
Use of antipseudomonal cephalosporins 4.0 (1.8–9.0) 0.001 4.1 (1.5–11.2) 0.005
Isolation of SM within 30 days 16.4 (6.7–39.6) 0.019 12.0 (3.5–40.3) ,0.001
SM, S. maltophilia; PA, P. aeruginosa; AC, Acinetobacter species; OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0112208.t002
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USA). All positive cultures were gram stained and subcultured on
blood agar plates and bromothymol blue (BTB) agar plates for
further identification. An automatic identification system, the
Vitek2 system (bioMe´reux, Marcy l’Etoile, France), and the Micro
Scan WalkAway (Siemens Healthcare Diagnostics, Tokyo, Japan)
were used to identify SM, PA, and AC. The antimicrobial
susceptibilities were evaluated using the broth microdilution
method, and were categorised according to the 2012 Clinical
Laboratory Standard Institute (CLSI) breakpoints [13]. For agents
without published CLSI criteria for SM, the relevant criteria for
non-Enterobacteriaceae were used [13]. To test the susceptibilities
of SM and AC to tigecycline, an Etest (bioMe´reux, Marcy l’Etoile,
France) was performed using Iso-Sensitest agar [14].
DNA genotyping
The automated rep-PCR Diversilab Microbial Typing System
(Sysmex-bioMe´reux, Marcy l’Etoile, France) was used to investi-
gate the clonal relationship of the SM isolates, according to
manufacturer’s recommendations. The resulting analysis was
performed using the Diversilab software (version 3.4), which uses
the Pearson correlation coefficient to determine the distance
matrices and the unweighted pair group method with arithmetic
averages to create dendrograms. Isolates with a similarity of at
least 95% were considered a cluster.
Statistical analysis
The categorical variables were compared using the Chi squared
test or Fisher’s exact test. The continuous variables were compared
using the Mann-Whitney U test. To determine the independent
risk factors for SM bacteraemia and for the 30-day all-cause
mortality, all of the variables with a p-value of ,0.05 based on
univariate analyses were subjected to further selection using a
forward stepwise logistic regression. The survival curves for the
patients with SM, PA, and AC bacteraemia were prepared
according to the Kaplan-Meier method. The log-rank test was
used to compare the survival curves. A p-value of ,0.05 was
considered to be statically significant. We conducted our statistical
analyses with Stata version 11.2 (StataCorp, College Station, TX,
USA).
Results
We identified 54 patients with SM bacteraemia, 167 patients
with PA bacteraemia, and 69 patients with AC bacteraemia. No
patients with bacteraemia were positive for more than one
bacterial species.
Table 1 lists the results of the univariate analysis of the clinical
characteristics of the SM, PA, and AC groups. All of the SM
patients, 82.0% of the PA patients, and 89.9% of the AC patients
had nosocomial bacteraemia. Seventeen patients in the SM group
had received TMP-SMZ within 14 days of the onset of
bacteraemia for prophylaxis against Pneumocystis jirovecii pneu-
monia (trimethoprim 80 mg daily). Breakthrough infection (bac-
teraemia during TMP-SMZ prophylaxis) was observed in 9
patients, and 4 patients developed TMP-SMZ resistant SM
bacteraemia. When compared with the PA and AC groups, the
SM patients were characterised by a longer hospital stay, receiving
intensive care, an indwelling catheter, previous antimicrobial
therapy, and the isolation of SM within 30 days. Urinary tract
infections were not observed in the SM group, whereas these
infections were found in 14.4% of the PA patients. An elevated
SOFA score, solid organ transplantation, previous treatment with
aminoglycosides, and respiratory infectionwere significantly more
common in the SM group than in the AC group. Multivariate
analysis with each control (the PA and the AC groups) revealed
that the same factors were independently associated with SM
bacteraemia, including previous treatment with carbapenems or
antipseudomonal cephalosporins and isolation of SM within 30
days (Table 2).
Forty-eight patients in the SM group (88.9%) underwent
microbiological examinations within 30 days prior to the onset
of bacteraemia as a part of routine clinical practice. The number
of specimens obtained from each patient ranged 3 to 64 (median:
14.5). Thirty-two patients (66.7%) had previously been positive for
SM. The median duration between the first isolation of SM and
the onset of bacteraemia was 11 days (interquartile range: 3–20
days). The most frequent site of previous isolation of SM were
lower respiratory tract (96.8%, 30 of 31 examined patients),
followed by biliary tract (53.8%, 7 of 13 patients), peritoneal cavity
(27.3%, 6 of 22 patients), and central venous catheter tip (17.4%, 4
of 23 patients). Table 3 demonstrates the association between the
previous SM isolation site and the focus of SM bacteraemia.
Table 3. Previous S. maltophilia isolation site among the 32 S. maltophilia bacteraemic patients and the corresponding focus of
bacteraemia.
Focus of bacteraemia
Site of S. maltophilia isolation within 30 days prior to











Identical to the previous isolation
site (secondary bacteraemia)
8 (26.7) 3 (42.9) 2 (33.3) 2 (50.0) 15 (46.9)
Other site 13b (43.3) 3c (42.9) 3d (50.0) 1e (25.0) 7f (21.9)
Primary bacteraemia 9 (30.0) 1 (13.7) 1 (16.7) 1 (25.0) 10 (31.3)
aAll of the specimens were obtained from drainage tubes.
bCatheter-related, n = 8; biliary tract, n = 3; peritoneal cavity, n = 2.
cRespiratory tract, n = 1; peritoneal cavity, n = 1; catheter-related, n = 1.
dRespiratory tract, n = 1; biliary tract, n = 1; catheter-related, n = 1.
ePeritoneal cavity.
fCatheter-related, n = 6; biliary tract, n = 1.
doi:10.1371/journal.pone.0112208.t003
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Fifteen patients (46.9%) were considered as having secondary
bacteraemia from the previous isolation sites, and 10 patients
(31.3%) were considered as having primary bacteraemia. Among
the 7 patients considered as bacteraemia from another site of
infection, 6 had catheter related infections and 1 patient had a
biliary tract infection.
Figure 1. Kaplan-Meyer survival curves for patients with bacteraemia caused by S. maltophilia (SM), P. aeruginosa (PA), and
Acinetobacter species (AC). Panel A shows the all-cause mortality, and panel B shows the attributable mortality. The p-values were calculated using
the log-rank test. The median times and interquartile ranges to death among the SM, PA, and AC patients were 8.5 (2–18), 5 (2–21.5), and 12 (3.5–
24.5) days for the all-cause mortality and 3.5 (2–11.5), 2 (1–7), and 5 (1–14) days for the attributable mortality, respectively.
doi:10.1371/journal.pone.0112208.g001
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The SM group received inappropriate antimicrobial therapy
more frequently than the PA or the AC group (p,0.001 for each).
The 30-day all-cause and attributable mortality rates among the
SM group (33.3% and 22.2%, respectively) were higher than the
rates in the PA and AC groups, although a significant difference
was only observed in the comparison of the all-cause mortality of
the AC group (17.4%, p= 0.041). Fig. 1 shows the Kaplan-Meier
survival curves for the SM, PA, and AC groups.
The risk factors for the 30-day all-cause mortality in the SM
group, according to the univariate analysis, are shown in Table 4.
An elevated Charlson or SOFA score, septic shock, ICU stay,
mechanical ventilation, continuous renal replacement therapy,
and the presence of a urethral catheter or drainage tube were





(N=36) OR (95%CI) p-value
no. (%) no. (%)
Sex (male) 7 (36.8) 19 (52.8) 0.6 (0.2–0.8) 0.336
Age, median (IQR) 51.5 (42–62.3) 57.5 (39.3–66.8) 0.640
Duration of hospital stay, median (IQR) 51 (28.3–100.3) 46.5 (28–101.8) 0.993
Polymicrobial infection 5 (27.8) 8 (22.2) 1.3 (0.4–4.9) 0.448
Underlying diseases
Solid malignancy 7 (38.9) 14 (38.9) 1.0 (0.3–3.2) 0.619
Haematological malignancy 1 (5.6) 6 (16.7) 0.3 (0.03–2.7) 0.403
Diabetes 4 (22.2) 8 (22.2) 1.0 (0.2–3.9) 1.000
Renal dysfunction 5 (27.8) 4 (11.1) 3.1 (0.7–13.3) 0.142
Heart disease 4 (22.2) 4 (11.1) 2.3 (0.4–10.5) 0.418
Liver disease 7 (38.9) 12 (33.3) 1.3 (0.4–4.1) 0.456
Lung disease 1 (5.6) 2 (5.6) 1.0 (0.08–11.8) 1.000
Autoimmune disease 4 (22.2) 5 (13.9) 1.8 (0.4–7.6) 0.461
Charlson score, median (IQR) 4 (3–6) 2.5 (2–4) 0.033
Medical condition
SOFA score, median (IQR) 13.5 (7–14.3) 4 (2–7) ,0.001
Septic shock 11 (61.1) 5 (13.9) 9.7 (2.6–37.1) ,0.001
Solid organ transplantation 8 (44.4) 9 (25.0) 2.4 (0.7–7.9) 0.147
Bone marrow transplantation 1 (5.6) 4 (11.1) 0.5 (0.04–4.5) 0.655
Surgery within 30 days 8 (44.4) 9 (25.0) 2.4 (0.7–7.9) 0.147
Neutropenia 2 (11.1) 6 (16.7) 0.6 (0.1–3.5) 0.704
ICU stay 12 (66.7) 7 (19.4) 8.3 (2.3–29.8) 0.001
Immunosuppressive agents 12 (66.7) 17 (47.2) 2.2 (0.7–7.3) 0.177
Mechanical ventilation 13 (72.2) 9 (25.0) 7.8 (2.1–28.0) ,0.001
Maintenance-haemodialysis 0 (0.0) 3 (8.3) 0.3 (0.01–5.3) 0.543
CRRT 7 (38.9) 3 (8.3) 11.0 (2.4–49.3) 0.011
Central venous catheter 15 (83.3) 21 (58.3) 3.5 (0.9–14.5) 0.066
Urethral catheter 15 (83.3) 19 (52.8) 4.5 (1.1–18.1) 0.027
Nasogastric tube 12 (66.7) 17 (47.2) 2.2 (0.7–7.3) 0.177
Drainage tube 14 (77.8) 17 (47.2) 3.9 (1.1–14.2) 0.032
SM isolation within 30 daysa 12 (70.6) 20 (64.5) 1.3 (0.3–4.8) 0.757
Site of infection
Respiratoryb 5 (27.8) 3 (8.3) 4.2 (0.9–20.3) 0.100
Catheter-relatedb 1 (5.6) 11 (30.6) 0.1 (0.2–1.0) 0.044
Intra-abdominal 3 (16.7) 9 (25.0) 0.6 (0.1–2.6) 0.730
Primary 9 (50.0) 13 (36.1) 1.7 (0.5–5.6) 0.386
Inappropriate empiric therapy 6 (33.3) 11 (30.6) 1.1 (0.3–3.8) 0.836
OR, odds ratio; CI, confidence interval; IQR, interquartile range; SOFA, Sequential Organ Failure Assessment; ICU, Intensive care unit; CRRT, continuous renal replacement
therapy.
aMicrobiological examinations were performed in 17 non-survivors (94.4%) and in 31 survivors (94.4%).
bPatients with respiratory tract infections had a significantly higher risk for mortality than patients with catheter-related infections (OR, 18.3; 95% CI, 1.5–223; p = 0.018).
doi:10.1371/journal.pone.0112208.t004
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associated with the 30-day mortality of SM patients. Catheter-
related infections were associated with survival. Inappropriate
antimicrobial therapy was not associated with a poor prognosis.
The SOFA score was independently associated with 30-day
mortality (OR: 1.3; 95% CI: 1.1–1.5) according to the multivariate
analysis.
Table 5 shows the antimicrobial susceptibilities of the three
groups. The SM isolates had high susceptibility rates to
minocycline (100%), tigecycline (94.4%), TMP-SMZ (81.5%),
and levofloxacin (79.6%).
No apparent outbreak of SM bacteraemia was observed during
the study period. DNA genotyping using the Diversilab system of
the 54 SM isolates showed that 20 isolates belonged to the same
cluster. One cluster contained four isolates, whereas the other
eight clusters contained two isolates each (Fig. 2). The isolates that
belonged to each cluster were not epidemiologically related; the
related strains were detected in distant wards, or there was a
period of greater than six months between the detection of the
related strains.
Discussion
This is the first study that investigated the risk factors for SM
bacteraemia in all hospitalised patients, in comparison with other
major non-fermentating gram negative bacilli. Independent risk
factors found to be associated with SM bacteraemia included the
use of carbapenems and antipseudomonal cephalosporins and the
isolation of SM within 30 days. The SOFA score was an
independent prognostic factor.
Many studies have reported that the majority of the SM patients
have haematological malignancies, with a rate ranging from 29%
to 57% [5,7,15–17]. In our study, SM patients commonly had
solid malignancies (38.9%) and chronic liver diseases (35.2%), or
underwent solid organ transplantation (31.5%); patients with
haematological malignancies (13.0%) or bone marrow transplant
recipients (9.3%) were less common. Greater than 60 patients per
year underwent liver transplantation in this hospital. Solid organ
transplant recipients undergo surgical procedures and they are
exposed to mechanical ventilation, haemodialysis, drainage or
vascular catheter insertion, and broad-spectrum antimicrobials for
a long period of time. These features might be one reason why our
SM bacteraemia cases were associated with solid organ transplant
recipients more than with bone marrow transplant recipients.
The use of carbapenems and antipseudomonal cephalosporins
were the independent risk factors for SM bacteraemia. The risk
factors for SM bacteraemia when compared with Escherichia coli
bacteraemic or non-bacteraemic patients have included the use of
carbapenems, glycopeptides, aminoglycosides, central venous
catheter [5,7]. The use of cefepime or other antipseudomonal
drugs including aminoglycosides has been described as the risk
factors for SM infection in patients with critically ill trauma or
cystic fibrosis [18,19]. In univariate analysis with the AC group,
the use of aminoglycosides was also the risk factor. SM is generally
considered as resistant to antipseudomonal beta-lactams and
aminoglycosides. Therefore, it is presumed that use of these agents
may predispose to SM colonization or infection. The use of
glycopeptides was also the risk factor for SM in univariate analysis,
but this was not significant in multivariate analysis. The SM
patients who were previously treated with glycopeptides were
frequently treated with carbapenems or antipseudomonal cepha-
losporins. The previous use of prophylactic TMP-SMZ was not a
negative risk factor for SM bacteraemia, and breakthrough SM
bacteraemia occurred in approximately half of the patients and
was frequently associated with TMP-SMZ resistance. Low dose
treatment with TMP-SMZ might allow breakthrough infection
and predispose the patient to resistant bacteraemia.
Another independent risk factor for SM bacteraemia was
isolation of SM within 30 days. No previous study had indicated
that the isolation of SM was an independent risk factor for SM
bacteraemia. Nseir et al. [20] found that 80% of patients infected
with SM had prior isolation of SM, although the association
between colonization and infection was not evaluated. In case of
A. baumanii bacteraemia, one case-control study identified that
colonization with A. baumanii was the most significant risk factor
[21]. The previous isolation site might be of value for predicting
the source of bacteraemia because approximately half of the
patients had secondary bacteraemia. The majority of cases of
bacteraemia from sites other than the previous isolation site were
central venous catheter-related cases. This result might be
associated with the fact that a specimen from a vascular catheter
tip could not be easily obtained and is often removed after
presence of bacteraemia.
Compared to both control groups, mechanical support,
intensive care, and indwelling catheters were significant risk
factors for SM bacteraemia, although these factors were not
independent. Mechanical ventilation and ICU stay has been
shown as risk factors of SM infection [22,23]. SM adheres to the
abiotic surfaces of medical implants or indwelling catheters and an
association between colonization of SM and prosthetic devices has
been observed [24]. Therefore, these devices may play a role in the
Table 5. Antimicrobial susceptibilities of the blood isolates of S. maltophilia, P. aeruginosa, and Acinetobacter species.
Antibiotics SM (N=54), % PA (N=167), % AC (N=69), %
Amikacin 11.1a 96.4 97.1
Levofloxacin 79.6 76.9b 95.7
Meropenem 0.0a 76.6 95.7
Ceftazidime 42.6a 92.9 85.5
Cefepime 3.7a 88.5 88.4
TMP-SMZ 81.5 ND 91.2
Minocycline 100.0 ND 98.6
Tigecycline 94.4 ND 98.6
TMP-SMZ, trimethoprim-sulfamethoxazole; SM, S. maltophilia; PA, P. aeruginosa; AC, Acinetobacter species; ND, not done.
aThe susceptibility rate was significantly lower compared with PA or AC isolates.
bAnalysis of the susceptibility was performed for the 157 available isolates.
doi:10.1371/journal.pone.0112208.t005
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occurrence of SM bacteraemia. Urinary tract infections were more
frequently observed in the PA group than in the SM group. Well-
documented cases of SM urinary tract infections are rare [25,26],
whereas PA often causes urinary tract infections in a hospital
setting [27]. A history of solid organ transplantation was more
frequently observed among the SM group than the AC group. The
SM patients who received solid organ transplantation prior to
bacteraemia were frequently received carbapenems and antipseu-
domonal cephalosporins.
In the univariate analysis, SM bacteraemic patients with
catheter-related infections had better outcomes compared with
other sites of infection or respiratory tract infections; these results
are consistent with the results of previous studies [28,29]. The
severity of the illness was related to the poor outcome of SM
bacteraemia, and administration of the inappropriate antimicro-
bial treatment was not associated with increased mortality. The
impact of early empirical treatment on SM infection remains to be
elucidated [30]. Some studies suggest that bacteraemia due to SM
was directly influenced by the conditions of each patient
[15,16,26,28,31]. However, other studies have reported that the
initial administration of the inappropriate antibacterial treatment
to patients was a significant predictor of mortality [5,17,18,32–33].
Antimicrobial therapy for SM infection is problematic because
many isolates are resistant to multiple agents used to treat gram-
negative infections. In our study, isolates of the SM group showed
antimicrobial susceptibilities that were distinct from those of the
PA and the AC groups, and the SM group frequently received
inappropriate empiric antimicrobial therapy. Similar to previous
reports, the SM isolates in this study were resistant to beta-lactams
and aminoglycosides. The resistance of SM to TMP-SMZ is
problematic when treating SM infection. The resistance rates are
reported to be between 8% and 18% in the Asia-Pacific, and the
SM isolates in the present study showed a similar resistance rate
[1,34]. Levofloxacin may be an alternative drug to treat SM
infection [35]. Recent studies indicated that levofloxacin was not
inferior to TMP-SMZ for the treatment of SM infection or
bacteraemia [36,37]. However, rapid resistance to fluoroquino-
lones has been observed in vitro and in vivo [2]. Minocycline,
which was active against all of the SM isolates, may also be used to
treat SM infection, although its clinical application is still limited
[2].
DNA genotyping using the Diversilab system revealed that the
majority (63%) of the SM isolates were genetically unrelated.
Among the genetically related isolates, no epidemiological linkage
was observed, and these results suggest that there were no
outbreaks during the study period. The SM clinical isolates also
showed high genodiversity in previous reports [5,38].
The present study has several limitations that should be
acknowledged. First, it was retrospectively performed at a single
institution. Second, although this is the largest study to investigate
the risk factors of SM bacteraemia, the number of patients in the
SM group may still be too small to analyse the prognostic factors of
SM bacteraemia. Third, although prior SM isolation was the
independent risk factor for SM bacteraemia, we could not perform
an active surveillance culture for SM. Active surveillance cultures
to predict the occurrence of drug-resistant gram-negative bacter-
aemia have been reported as a useful method for guiding empiric
therapy in critically ill patients [39]. Eighty-nine percent of our
patients underwent at least 3 bacterial cultures, and SM was
recovered from as many as 66.7% of patients. We believe that this
finding justifies further research evaluating the effect of active
surveillance for SM.
In conclusion, SM bacteraemia was associated with longer
hospital stay, higher mortality and inappropriate empiric antimi-
crobial therapy compared to bacteraemia due to other major non-
fermentative, gram-negative bacilli. In our study, the use of
carbapenems and antipseudomonal cephalosporins in the 14 days
prior to bacteraemia and the isolation of SM within 30 days were
significant risk factors for the development of SM bacteraemia.
Furthermore, the judicious use of antipseudomonal beta-lactams is
Figure 2. Genotyping of the 54 S. maltophilia isolates using the
Diversilab system. Twenty isolates belonged to nine clusters. One
cluster contained four isolates, whereas the other eight clusters
contained two isolates each.
doi:10.1371/journal.pone.0112208.g002
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needed, as our study suggests that these agents are a risk factor for
developing SM bacteraemia.
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